There are currently 67 clinical trials in Chula Vista, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Profil Institute for Clinical Research Inc., GSK Investigational Site, GW Research, Inc and eStudySite. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
NCT06150924
Recruiting
This is a 2-part study evaluating the efficacy and safety of lorundrostat (an aldosterone synthase inhibitor [ASI]) for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) either in combination with dapagliflozin, or alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Balboa Nephrology Medical Group, Inc. (BNMG) - California Institute of Renal Research (CIRR) - Chula Vista, Chula Vista, California
Conditions: Chronic Kidney Disease
Register for Updates
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2024
Locations: Sharp Chula Vista Medical Center, Chula Vista, California
Conditions: Crohn Disease
Register for Updates
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760
Recruiting
This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Travere Investigational Site, Chula Vista, California
Conditions: Immunoglobulin A Nephropathy
Register for Updates
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
NCT06036784
Recruiting
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses and Drug Drug Interaction of MBX 1416 in healthy volunteers This study includes 3 parts. Part A involves a single dose of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part B involves repeat doses of MBX 1416 or placebo taken as a subcutaneous injection (SC). Part C involves the evaluation of rosuvastatin and acetaminophen pharmacokinetics in the pr... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/20/2024
Locations: ProSciento CRU, Chula Vista, California
Conditions: Postbariatric Hypoglycemia
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
02/12/2024
Locations: Not set, Chula Vista, California
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
NCT05587309
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/30/2024
Locations: Research Site 94, Chula Vista, California
Conditions: Erosive Esophagitis
Register for Updates
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919
Recruiting
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: Velocity Clinical Research, Chula Vista, California
Conditions: Severe Hypertriglyceridemia
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Precision Research Institute, Chula Vista, California +2 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Sharp Healthcare - 1150, Chula Vista, California
Conditions: Non Small Cell Lung Cancer
Register for Updates
Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
NCT05660382
Recruiting
The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants w... Read More
Gender:
All
Ages:
All
Trial Updated:
01/15/2024
Locations: Head and Neck Surgery Specialist, Chula Vista, California
Conditions: Otomycosis
Register for Updates
Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California
NCT05022472
Recruiting
The United States (U.S.) is the country with the largest number of infections and deaths due to COVID- 19 and racial/ethnic minorities are disproportionately affected. Acceptance and uptake of COVID-19 vaccines will be instrumental to ending the pandemic. To this end, 2VIDA! (SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California) is a multilevel intervention to address individual, social, and contextual factors related to access to, and acceptance of, the COVID-19 vaccine by... Read More
Gender:
All
Ages:
Between 16 years and 99 years
Trial Updated:
01/11/2024
Locations: San Ysidro Health Chula Vista, Chula Vista, California
Conditions: Vaccine Refusal, Covid19
Register for Updates
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
NCT05342623
Recruiting
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind 12-week Treatment Period (Treatment Period 1),... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/02/2024
Locations: Cara Therapeutics Study Site, Chula Vista, California
Conditions: Chronic Kidney Diseases, Pruritus
Register for Updates